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is an equally efficacious alternative to urinary derived FSH, Menopur®. One differ-
ences between these products is their delivery devices; Gonal f® is provided as a 
multidose pen, Menopur® in vials or multidose preparation, and Bemfola® as a fixed 
dose pen. The aim of this study was to determine the impact of delivery device on 
drug wastage and associated cost. Methods: A retrospective analysis of Gonal-f® 
and Menopur® prescription and usage data from five UK infertility clinics was 
conducted to identify the level of wastage occurring from IVF cycles. Data collected 
included: number IVF cycles conducted in previous 12 months; daily dose; length 
of treatment; dose adjustment following ultrasound scan and FSH formulation(s) 
prescribed. The drug wastage for each patient was calculated and results compared 
to the potential Bemfola® wastage for these patients. The wastage cost was then 
determined using NHS list prices. Results: A total of 4724 IVF cycles were incor-
porated into the analysis. Of the 4078 Gonal-f® cycles, overall drug wastage was 
650,775IU (5.7% of total dose prescribed) equating to 160IU per patient. For the 646 
Menopur® cycles the wastage was 190,163IU (11.6% of total dose prescribed) equat-
ing to 294IU per patient. Had Bemfola® been used in these patients, the wastage 
would have been reduced to 104IU and 61IU per patient respectively. The use of 
Bemfola®, across all cycles, results in a drug wastage reduction of 376,800IUs and an 
associated cost saving of £100,011. Extrapolating this data to the annual number of 
UK IVF cycles results in a potential cost saving of £1,157,579. ConClusions: Using 
Bemfola® as an alternative to Gonal-f® or Menopur® can potentially reduce drug 
wastage and associated costs to both patients and the NHS.
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objeCtives: To conduct a cost-effectiveness analysis of abobotulinumtoxinA+ 
standard therapy (ST), onabotulinumtoxinA+ST and standard therapy solely in 
patients with spastic cerebral palsy in Russia for 2-year period. Standard therapy 
includes centrally acting muscle relaxant, physiotherapy, casting and ortho-
sis. Methods: A decision tree model used to simulate the effects of abobotuli-
numtoxinA, onabotulinumtoxinA and standard therapy. The data on drugs efficacy 
(measured as proportion of patients with spastic forms of cerebral palsy, avoided 
orthopedic surgery at 2nd year of therapy) was obtained from available clinical tri-
als. In the long term, surgery in older children with cerebral palsy have lower risk 
of recurrence compared with the operations carried out in early childhood. In this 
regard, there is a particular importance of botulinum toxin therapy effect on the 
likelihood of reducing the frequency of the orthopedic surgeries or postponing them 
at a later period by reducing spasticity and prevent contractures. The following costs 
were taken into account: the costs of pharmacotherapy, inpatient and outpatient 
care, costs of adverse events, sanatorium-resort medical care, casting orthopedic 
surgeons, disability pensions, disable child care benefit. Results: It was revealed 
that the abobotulinumtoxinA+standard therapy helps to avoid surgical intervention 
in 93% of patients compared to 90% of patients with onabotulinumtoxinA+standard 
therapy and for 48% of patients with standard therapy. It was found that the regi-
men abobotulinumtoxinA+standard therapy has the lowest cost-effectiveness ratio 
(11,509 RUB/215 $) in comparison with drug therapy onabotulinumtoxinA+standard 
therapy (12 872 RUB/ 238 $) and standard therapy with a centrally acting mus-
cle relaxant without BTA (27 715 rubles/467 $) by the end of 2 years of treat-
ment. ConClusions: Treatment scheme abobotulinumtoxinA+standard therapy 
is considered the most cost-effective one for spastic cerebral palsy therapy in the 
Russian Federation compared with onabotulinumtoxinA+standard therapy and 
standard therapy solely.
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objeCtives: To estimate the lifetime indirect cost of childhood overweight and 
obesity for Germany. Methods: An incidence-based lifetime cohort model was 
developed using Markov modelling approach. The model consisted of two parts: (a) 
Model I used German data on prevalence of BMI categories (normal weight, over-
weight and obesity) during childhood and adolescence to evaluate BMI trajectories 
before the age of 18; and (b) Model II analysed the lifetime BMI trajectories based on 
the history of childhood BMI and estimated lifetime excess indirect cost attribut-
able to childhood overweight and obesity. The model used data from the German 
Interview and Examination Survey for Children and Adolescents (KiGGS) and the 
German Microcensus 2009. Indirect costs were defined as the opportunity cost of 
lost productivity due to morbidity or early mortality and were identified through 
a systematic literature review. Results: Our analysis showed that the majority 
of overweight and obese children remained in the same BMI category during their 
adult life, resulting in significant indirect costs over the lifetime. We estimated that 
overweight and obesity during childhood resulted in an excess lifetime cost per 
person of 4,209 EUR (discounted at 3%) for men and 2,445 EUR (discounted at 3%) 
for women. For the current prevalent German population, the excess lifetime cost 
of overweight and obesity was 145 billion EUR (discounted at 3%). ConClusions: 
Our study showed that overweight and obesity during childhood results in signifi-
cant economic burden on the society. Therefore, cost-effective strategies targeted 
at reducing the prevalence of obesity during the early years of life can significantly 
reduce both healthcare and non-healthcare costs over the lifetime.
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IBM SPSS for windows statistical software version 20 (SPSS Inc, Chicago, USA). Data 
was presented using descriptive statistics (i.e. numbers, percentages). Results: A 
total of 450 questionnaires were administered to the respondent. After exclusion, 
finally 378 respondents were included. Majority of the respondents (94%) accepted 
their habit of practicing self-medication. In this study, 86% of the respondents were 
found to have habit of advising medicines to others, while 70% respondents tried 
medicines according to their friend’s suggestion. Most common reason cited for self-
medication was found to be convenience (42%), followed by quick relief (21%), time 
saving (13%), economical (10%) and others (14%). ConClusions: Self-medication 
is highly prevalent in pharmacy students. One potential reason could be the easy 
availability of wide range of drugs without prescription.
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objeCtives: To measure all those risk factors of danger that may lead to intrau-
terine death. To introduce the frequency of intrauterine death related to maternal 
origins and the diseases of the foetus. Methods: Our research was carried out in 
Teaching Hospital Markusovszky, Szombathely. We examined 50 pregnancies fol-
lowed by intrauterine death by document analysis between the period of 1 January, 
2007 and 31 December 2014. We applied average and frequency calculation within 
descriptive statistical methods for analyzing data. Defining the relation between the 
two variants, we calculated chi2 probability (p< 0,05). Results: Significant differ-
ences can be seen between incidence rate of foetal death regarding singular preg-
nancies CI 0,78-0,97 and multiple pregnancies CI 0,02 - 0,21; as well as in terms of 
foetal death between undeveloped foetus CI 0,23-0,49 and developed foetus between 
CI 0,50-0,76. Our examination found that in most cases there were maternal pre-
disposing factors, operation carried out previously on the mothers, and circulatory 
diseases (p> 0,05) which were followed by endocrin diseases (p> 0,05). The most 
frequent predisposing factors of the foetus were placenta abnormalities in particu-
lar placenta abruptio. According to our examination, the riskiest period in terms 
of intrauterine death is between 25-30 gestational weeks. There were 19 (38%) boy 
and 33 (66%) girl foetus morti. The most frequent intrauterine deaths are among 
the foeti of 501-1000 grams and 31-35 centimeters. According to our examination 
maternal predisposing factors were hypoxia, multiple pregnancy, obesity, hyper-
thyroidism and smoking. The following risk factors of foetus occured: dysmaturity, 
abruptio placentae, polihydramnion, premature birth, developmental abnormality 
of the foetus. ConClusions: For the decrease in number of intrauterine deaths, 
it would be extremely important to record accurate maternity anamnesis. In our 
view, with early identification of exposure to risk, prevention of complications and 
its early identification, stillbirths can be reduced
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objeCtives: To develop an interactive tool to estimate the budget impact of implant 
versus daily oral contraception (OC) use over a 3-year time horizon. Methods: A 
previously developed and published decision-analytic model was adapted to build 
an interactive tool in which users can evaluate the costs of implant and OC use 
over 3-years (healthcare payers’ perspective) for a given population and by custom-
izing some model inputs. Costs associated with a population of women initiating 
each method are calculated at the end of each year and for 3 years cumulatively. 
The model allows method discontinuation throughout time followed by switch to 
another hormonal contraceptive or drop out. Pregnancy and contraceptive costs 
incurred after switching or drop out are allocated to the starting contraceptive 
method. Model inputs: 1) contraceptive methods discontinuation and failure rates; 
2) risk of dropping out contraception and due probability of getting pregnant; 3) 
market share for hormonal contraceptives; 4) pregnancy outcomes probability and 
costs; 5) contraceptive and medical follow-up costs. Model outputs are unplanned 
pregnancies and costs. Default scenario is presented for national level (Portuguese 
sources of data were used when available, including unit costs). Results: National 
default results were calculated for 1000 women. Implant utilization was associated 
with higher costs at the 1st year (due to its acquisition and insertion). For the 2nd, 
3rd year and for cumulative results OC was associated with higher costs due to 
higher risk of unplanned pregnancies. ConClusions: A tool was created to provide 
healthcare stakeholders with the opportunity to perform a customized analysis 
and to make evidence-based decisions considering the economic perspective when 
assessing the most appropriate methods to offer women in the NHS setting. In the 
Portuguese default scenario implant initial acquisition and insertion costs are offset 
by decreased pregnancy related costs, when comparing with OC use during 3 years
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objeCtives: Bemfola®, an EMA approved Gonal-f® biosimilar, is a recombinant 
follicle-stimulating hormone (rFSH) used for in-vitro fertilisation (IVF). Bemfola® 
